ClinicalTrials.gg
RecruitingNCT06111599Tevi-LuSyUpdated Nov 1, 2023

Thermovision-controlled Lumbar Sympathetic Blockade in Chronic Limb-threatening Ischemia Treatment

An interventional study of lumbar sympathetic blockade in Chronic Limb-Threatening Ischemia, sponsored by Europainclinics z.ú.. Recruiting at 1 site in Slovakia. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Europainclinics z.ú. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Thermovision-controlled lumbar sympathetic blockade in chronic limb-threatening ischemia treatment

Read the detailed description

Chronic limb-threatening ischemia (CLTI), the end-stage of lower extremity artery disease (LEAD), occurs with growing prevalence around the globe and is associated with increased healthcare costs. CLTI is defined by the presence of LEAD in combination with rest pain, gangrene, or lower limb ulceration lasting more than two weeks. Despite unclear results of abdominal surgical lumbar sympathectomy, novel interventional minimally invasive fluoroscopy-guided procedures seem to be promising. A prospective interventional study will be conducted, primarily targeting patients afflicted by critical limb ischemia, with the incorporation of thermal vision control and tissue oxygen monitoring.

02

Conditions studied

  • Chronic Limb-Threatening Ischemia
03

In context

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

This study's planned enrollment of 60 is above the median of 41 across 240 interventional studies indexed under Chronic Limb-Threatening Ischemia.

Browse Chronic Limb-Threatening Ischemia studies →

Lead sponsor

Europainclinics z.ú. is the lead sponsor of 11 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic limb-threatening ischemia-Patients with chronic leg pain for at least 6 months with intensity (VAS >=5)
  • those who (only if a signature was obtainable), or whose legal guardian,fully understood the clinical trial -details and signed the form

Exclusion criteria

Exclusion Criteria:

  • Chronic Venous Insufficiency
  • women with positive a pregnancy tests before the trial or who planned to become pregnant within the following 3 years
  • other patients viewed as inappropriate by the staff
  • disagreement with participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A

    Proximal arterial obliteration

    Procedure: lumbar sympathetic blockade

  • Experimental
    Group B

    Distal arterial obliteration

    Procedure: lumbar sympathetic blockade

  • Experimental
    Group C

    Complex arterial obliteration

    Procedure: lumbar sympathetic blockade

Interventions

  • Procedurelumbar sympathetic blockade

    Skiascopic-guided lumbar sympathetic blockade with the administration of local anesthetic

06

What researchers measure

Primary outcomes

  1. Change From Baseline EuroQoL-5 Dimension (EQ-5D) Value 3m

    EQ-5D-5L self-care, usual activities, pain/discomfort and anxiety/depression

    Time frame: 3 months follow-up

  2. Change From Baseline EuroQoL-5 Dimension (EQ-5D) Value 6m

    EQ-5D-5L self-care, usual activities, pain/discomfort and anxiety/depression

    Time frame: 6 months follow-up

  3. Change From Baseline Visual Analog Pain Scale (VAS) of Back Pain 3m

    Change From Baseline Visual Analog Pain Scale (VAS) of Back Pain 3m measured by VAS 10 point measurement

    Time frame: 3 months follow-up

  4. Change From Baseline Visual Analog Pain Scale (VAS) of Back Pain 6m

    Change From Baseline Visual Analog Pain Scale (VAS) of Back Pain 6m measured by VAS 10 point measurement

    Time frame: 6 months follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — numerical rating scale of quality of life

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Aug 2024, 9 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2023
First posted
Nov 1, 2023
StartActual
Oct 22, 2023
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 31, 2026
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111599
Lead sponsor
Europainclinics z.ú.
Collaborators
Slovak Academy of Sciences
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Oct 22, 2023
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Nov 1, 2023

Study contacts

Ladislav Kočan, MD, PhD, FIPP
Contact
kocanladislav@gmail.com
+421907440250

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion